Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Tarantelli

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Haematologica|January 26, 2019
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agentsChiara Tarantelli, Lu Zhang, Elisabetta Curti, et al.
Cancers|June 26, 2025
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell LymphomasChiara Tarantelli, Filippo Spriano, Elisa Civanelli, et al.
British Journal of Haematology|July 30, 2019
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomasFilippo Spriano, Chiara Tarantelli, Eugenio Gaudio, et al.
British Journal of Haematology|December 9, 2022
In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103Filippo Spriano, Chiara Tarantelli, Alberto J Arribas, et al.
British Journal of Haematology|July 31, 2024
Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agentsFilippo Spriano, Chiara Tarantelli, Luciano Cascione, et al.
European Journal of Medicinal Chemistry|August 11, 2019
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell linesAnna Lucia Fallacara, Raffaele Passannanti, Mattia Mori, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like typeChiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, et al.
European Journal of Medicinal Chemistry|January 12, 2023
Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitorMartina De Pascale, Lukas Bissegger, Chiara Tarantelli, et al.
Ejhaem|September 2, 2022
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphomaFilippo Spriano, Giulio Sartori, Chiara Tarantelli, et al.
RSC Medicinal Chemistry|January 22, 2021
Understanding the mechanism of action of pyrrolo[3,2-<i>b</i>]quinoxaline-derivatives as kinase inhibitorsAndrea Unzue, Claudia Jessen-Trefzer, Dimitrios Spiliotopoulos, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Haematologica|January 26, 2019
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agentsChiara Tarantelli, Lu Zhang, Elisabetta Curti, et al.
Cancers|June 26, 2025
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell LymphomasChiara Tarantelli, Filippo Spriano, Elisa Civanelli, et al.
British Journal of Haematology|July 30, 2019
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomasFilippo Spriano, Chiara Tarantelli, Eugenio Gaudio, et al.
British Journal of Haematology|December 9, 2022
In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103Filippo Spriano, Chiara Tarantelli, Alberto J Arribas, et al.
British Journal of Haematology|July 31, 2024
Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agentsFilippo Spriano, Chiara Tarantelli, Luciano Cascione, et al.
European Journal of Medicinal Chemistry|August 11, 2019
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell linesAnna Lucia Fallacara, Raffaele Passannanti, Mattia Mori, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like typeChiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, et al.
European Journal of Medicinal Chemistry|January 12, 2023
Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitorMartina De Pascale, Lukas Bissegger, Chiara Tarantelli, et al.
Ejhaem|September 2, 2022
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphomaFilippo Spriano, Giulio Sartori, Chiara Tarantelli, et al.
RSC Medicinal Chemistry|January 22, 2021
Understanding the mechanism of action of pyrrolo[3,2-<i>b</i>]quinoxaline-derivatives as kinase inhibitorsAndrea Unzue, Claudia Jessen-Trefzer, Dimitrios Spiliotopoulos, et al.
Pageof 6